Srihari Gopal, MD

Medication Preference for Injectable Versus Oral Antipsychotics in Patients With Schizophrenia: Results From a Patient-Reported Questionnaire From a Double-Blind Randomized Controlled Study

Introduction: Assessing factors that determine patients’ preferences for long-acting injectable (LAI) or oral antipsychotics could help reduce potential barriers to LAI use in schizophren...

Clifton Blackwood , MD;

Panna Sanga , MD;

Isaac Nuamah , PhD;

Arun K. Singh , MD, PhD, MCh, MNAMS;

Alexander Keenan , MA, MS, MD;

Srihari Gopal , MD;

Maju Mathews , MD;

11/22/2019

Defining “Adequately Treated”: Characteristics of Patients With Schizophrenia Successfully Transitioned From Paliperidone Palmitate Once Monthly to Paliperidone Palmitate Once-Every-3-Months

Objective: To identify patient characteristics associated with successful transition to once-every-3-months paliperidone palmitate (PP3M).

Edward S. Kim , MD, FACP, MBA;

Amy O'Donnell , MD, JD, BS;

Sanjai Rao , MD;

Ibrahim Turkoz , PhD;

Srihari Gopal , MD;

11/22/2019

A Phase 3 Non-Inferiority Study Comparing Paliperidone Palmitate 1-Month vs 3-Month Long-Acting Injectables for Negative Symptom Improvement in Schizophrenia

Background: Negative symptoms of schizophrenia are predictors of long-term disability. Paliperidone palmitate 3-month formulation (PP3M) provides a sustained release of paliperidone, perm...

Edward S. Kim , MD, FACP, MBA;

Arun K. Singh , MD, PhD, MCh, MNAMS;

Katalin Pungor , PhD;

Maju Mathews , MD;

Jagadish Gogate , PhD;

Srihari Gopal , MD;

03/01/2019